Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses ibrutinib (Imbruvica), 140 mg capsule, oral.
 Indication: For the treatment of adult patients with:
 
 Waldenström macroglobulinemia (WM) as a monotherapy or in combination with rituximab
 Previously untreated active chronic lymphocytic leukemia (CLL), including patients with 17p deletion
 CLL who received at least one prior therapy, in combination with bendamustine and rituximab
 Relapsed or refractory mantle cell lymphoma (MCL)
 marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
 Steroid-dependent or refractory chronic graft vs. host disease (cGVHD)
 
 
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
